Cargando…
SQ-standardized house dust mite immunotherapy as an immunomodulatory treatment in patients with asthma
BACKGROUND: Specific immunotherapy is the only treatment with the potential to prevent progression of the allergic disease and the potential to cure patients. The immunomodulatory ability of SQ-standardized house dust mite (HDM) subcutaneous immunotherapy (SCIT) was investigated in patients with all...
Autores principales: | Blumberga, G, Groes, L, Dahl, R |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3039748/ https://www.ncbi.nlm.nih.gov/pubmed/20883456 http://dx.doi.org/10.1111/j.1398-9995.2010.02451.x |
Ejemplares similares
-
Efficacy analysis of three-year subcutaneous SQ-standardized specific immunotherapy in house dust mite-allergic children with asthma
por: HUI, YU, et al.
Publicado: (2014) -
New perspectives in allergen specific immunotherapy driven by big trials with house dust mite sublingual SQ(®) tablets
por: Vitiello, Gianfranco, et al.
Publicado: (2020) -
Cost utility analysis of the SQ(®) HDM SLIT-tablet in house dust mite allergic asthma patients in a German setting
por: Hahn-Pedersen, J., et al.
Publicado: (2016) -
Immunotherapy of house dust mite allergy
por: Yang, Lin, et al.
Publicado: (2017) -
Cost-effectiveness of SQ(®) HDM SLIT-tablet in addition to pharmacotherapy for the treatment of house dust mite allergic rhinitis in Germany
por: Green, William, et al.
Publicado: (2017)